Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
Listen to the original audio · Transcribed with NVIDIA Parakeet · Why times can differ in your player
Mm. Hi everybody, I'm Nikola Tangen, uh the CEO of the Norwegian So on Wealth Fund, and today I am in particularly good company with David Rix, the CEO of the pharma giant Elili. Now Elalele is spearheading, as you may know, the weight reducing drug revolution. We own more than one percent of the company, totaling eight billion dollars. Big thanks for coming, Dave. Great to be with you. Now, um the uh GLP one drug sends uh shockwaves through the world and
Now they seem to be curing everything from Alcoholism to Alzheimer's. So why are these drugs so efficient? Yeah. It's well it's certainly been a uh exciting time. For the company, but also for medical science, because this is actually not a very new idea. Yeah.
Um, Lily launched the first GLP one agonist in two thousand six. Um so almost twenty years ago Um, but it's a I think a good example of how the technology in medicine works. is that uh oftentimes um We know the sort of the the m the major theme, but
We already have this episode, so unlocking it is cheap and permanent: the full transcript (56 minutes, 10,222 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.
No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 5 episodes for $3.49, and monthly plans are cheaper still.